ClearPoint Neuro price to book ratio CLPT

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 25.9×
10-year median: 8.7×
Against its 10-year history: 87th; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.3× to 192×
Peer median: 2.6×

ClearPoint Neuro's price to book ratio is 25.9× as of Oct 23, 2026.

That is above its ten-year median of 8.7×, higher than on 87% of days in the last ten years.

Over that time it ranged from 2.3× in Sep 2017 to 192× in Apr 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 2.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	25.9×	9.2×	44.0×
2025	25.1×	12.0×	39.4×
2024	15.0×	4.3×	15.0×
2023	6.9×	4.2×	7.1×
2022	5.2×	3.9×	9.4×
2021	6.0×	6.0×	192×
2020	78.1×	8.4×	95.7×
2019	12.7×	7.0×	100×
2018	7.5×	3.6×	8.6×
2017	3.9×	2.3×	22.9×
2016	21.4×	13.3×	25.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest ClearPoint Neuro's size, closest first, today.

Company	Price to book ratio
CLPTClearPoint Neuro	25.9×
INFUInfuSystem	4.7×
UTMDUtah Medical Products	1.9×
EMBCEmbecta	n/m
PDEXPro DEX	4.2×
TCMDTactile Systems Technology	2.4×
MDXGMimedx	2.6×
MOVMovado	1.4×
KEQUKewaunee Scientific	1.3×
IRMDIradimed	10.8×
STAAStaar Surgical	3.1×
Peer median	2.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on ClearPoint Neuro

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.